Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,401–10,500 of 10,906
Wnuk, J. S., Bobola, A., Pietrzyński, Ł., & Gisterek, I. (2023) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2023.0024
Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation
Ribeiro, A. R. S., Eguskiza, A., Dang, H.-H., Neuper, T., Unger, M. S., Comas, L. R., Steiner, M., Sieberer, H., Zaborsky, N., Greil, R., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c06105 · Cited by 1
Intramuscular administration of LNP-mRNA therapeutics
Tanzadehpanah, H., Mahaki, H., Sheykhasan, M., Alavi-Kakhki, S. S., Sardou, H. S., Mobarezi, Z., Esfandiari, A. H., Meshkat, Z., Afkhami, H., & Manoochehri, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00015-x
Rojas, C., Spector, S. A., Cale, B., et al. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.3
Self-citationInzaule, S. C., Silva, R., Ford, N., Thwin, S. S., Jassat, W., Zumla, A. I., Doherty, M. C., Diaz, J., & Bertagnolio, S. (2026) · Medicine · doi:10.1097/md.0000000000049386
“[4] While COVID-19 vaccines have been widely administered, underrepresentation of PLHIV in clinical trials [5,6] limits our understanding of vaccine responses in this population.”
Akın, A., SAFİ, Y., Bektas, N. E., & DEMİR, H. A. (2024) · Coronaviruses · doi:10.2174/0126667975319329241010070145
A Novel CRISPR-Engineered, Stem Cell-Derived Cellular VaccinePreprint
Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., Mosher, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.28.474336
Ogbodo, S. C., Damba, J. J., Olaoye, O. C., & Ofili, D.-F. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4934548/v1
Peptide–Lipid Nanoparticles Enhance Cell Transfection Efficiency
Ye, Y., Hu, H., Yue, L., Su, R., Qi, W., & Wang, Y. (2026) · Langmuir · doi:10.1021/acs.langmuir.5c05962
Ruiz-Saez, H., Íñiguez, A. E., González‐Osorio, Y., Trigo-López, J., Sierra, Á., García, A. R., Planchuelo‐Gómez, Á., González-Celestino, A., Hurtado, M. L., Sierra, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13122900
Evaluating the Side Effects of COVID-19 Vaccines Available in Al-Diwaniyah Province
Kazaal, M. A., Jaythoom, R. A., Mahdi, N., & Mohammed, D. (2024) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_206_23
Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2)
Al‐Tawfiq, J. A., & Memish, Z. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-85877-3_50-1
Artificial intelligence can support the chemical design of multiepitope vaccine nanocarriers
Garcia-Atutxa, I., & Villanueva‐Flores, F. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00929-6 · Cited by 1
Petrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A. R., Meece, J. K., Belongia, E. A., & McLean, H. Q. (2022) · medRxiv · doi:10.1101/2022.04.15.22273915
Yao, Y., Yang, Y., Wu, Q., Liu, M., Bao, W., Wang, Q., Cheng, M., Chen, Y., Cai, Y., Zhang, M., et al. (2025) · European journal of medical research · doi:10.1186/s40001-024-02240-5 · Cited by 1
Predictors of COVID-19 Mortality: A Stratified 3 by 3 Factorial Correlation Analysis
Arori, W. O. (2026) · International Journal of Latest Technology in Engineering Management & Applied Science · doi:10.51583/ijltemas.2026.150500133
Nouveaux agents supramoléculaires anti-adhésifs contre SARS-cov-2
Boulo, L. (2024) · theses.fr (ABES) · doi:10.70675/540d01e6z0766z4fd5z804ezedabf2c230e9
Uncertainty, Vaccination, and the Duties of Liberal States
Huang, P.-H. (2022) · Philosophy of engineering and technology · doi:10.1007/978-3-031-08424-9_5
Chen, X., Agarwal, S., Hoelscher, S., Egan, R., Jaiswal, D., Stassinopoulos, A., Reed, R., McClure, J., & Kroll, W. (2021) · medRxiv · doi:10.1101/2021.05.06.21256544
Delamater, P. L., & Woodul, R. L. (2022) · medRxiv · doi:10.1101/2022.10.21.22281271 · Cited by 1
Elkousy, H. A., Khoriaty, J. D., Vidal, E. A., et al. (2022) · JSES Reviews Reports and Techniques · doi:10.1016/j.xrrt.2021.12.003
Zhou, Q., Eggert, T., Zhelyazkova, A., Choukèr, A., Adorjan, K., & Straube, A. M. (2024) · BMC Neurology · doi:10.1186/s12883-024-03583-6
Lanata, C. F., Ecker, L., Cornejo, R., Celis, C. R., Díaz-Parra, C. D. P., de León, S. A. R. P., Flores, O., Ochoa, M., Peña, B., & Gil, A. I. (2021) · Diagnóstico · doi:10.33734/diagnostico.v60i3.305
The Sprint to Develop Coronavirus Antivirals
Koehler, M. F. T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00578
Blinc, A., Buturović‐Ponikvar, J., & Fras, Z. (2022) · Strojniški vestnik – Journal of Mechanical Engineering · doi:10.5545/sv-jme.2022.64
Dedinská, I., Dadhania, D. M., Li, C., Hauser, N., Lamba, P., Lee, J. R., Muthukumar, T., & Suthanthiran, M. (2026) · medRxiv · doi:10.64898/2026.01.22.26344293
Ye, H., Jin, W., Feng, Y., Wu, Z., Sun, S., Cui, M., Lv, S., Jin, B., Liu, C., Wang, S., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3309-7
Csoma, E., Koroknai, Á. N., Sütő, R., Szilágyi, E. S., Pócsi, M., Nagy, A. C., Bíró, K., Kappelmayer, J., & Nagy, B. (2023) · Microorganisms · doi:10.3390/microorganisms11051187 · Cited by 2
Abbadi, D., Katsara, O., McConnell, R., Walters, B., Blanco, K. G., Canfrán‐Duque, A., Dornbaum, S., Andrews, J. J., & Schneider, R. J. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.033
Bayesian sequential probability ratio test for vaccine efficacy trials
Paul, E., Sutradhar, S., Hartzel, J. S., et al. (2024) · Computational Statistics · doi:10.1007/s00180-024-01458-5
American COVID: An Econometric Analysis of Variants
McIntosh, J. (2024) · Global Journal of Health Science · doi:10.5539/gjhs.v16n12p43
Divalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell- Penetrating Peptides
Maloverjan, M., Biswas, A., Padari, K., Abroi, A., Rebane, A., & Pooga, M. (2022) · European Peptide Symposium (EPS) · doi:10.17952/36eps/36eps.2022.117
Sonnleitner, S., Sonnleitner, S. T., Obererlacher, S., & Walder, G. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.115007
Plummer, M., & Franceschi, S. (2023) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_9-1
Catholic Doctrine Supports Religious Exemption to COVID-19 Vaccine Mandates
McKenna, K. C., McGovern, C., & Sabol, M. (2026) · The Linacre Quarterly · doi:10.1177/00243639261456061
Park, J., Lee, G., Lee, H., Kim, J., Kim, K., Kim, E., Lee, J., Lee, S., Youn, J., & Jang, Y. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103082
“6,7 This success was achieved through key technological advances, including improved mRNA stabilization techniques, nucleoside modifications such as N1-methylpseudouridine (m1 Ψ ), and optimized LNP delivery systems.”
Wang, Q., McManus, L. R., Levine, K. S., Blanc, R., Malca, H., Joughin, B. A., Bi, C., Keerti, K., Lauffenburger, D. A., Wesemann, D. R., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag106 · Cited by 1
Iloh, G. U. P., & Chukwuonye, M. (2023) · Journal of Primary Care Specialties · doi:10.4103/jopcs.jopcs_1_23
Chen, X., Jiang, L., Yang, H., Lu, J., Zhang, S., Dong, J., Li, H., Ye, Q., Jie, Z., Huimin, F., et al. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103406
Myocarditis After Administration of Messenger Ribonucleic Acid-1273 Vaccine
Soos, M. P., Ghareeb, G. S., George, V., Rahman, M., Holmes, K., Madala, M. C., Sulaiman, A., Burke, P., Kichloo, A., & Kanjwal, K. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001449
Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta DominancePreprint
Islam, N., Griffin, D. O., Jarvis, M. S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4145598
Jit, T., Paul, A., & Chowdhury, S. (2024) · The Open COVID Journal · doi:10.2174/0126669587357843241123141333
HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering
Kim, D. K., Moon, S.-J., Han, E. L., Feng, E., Murray, A. M., Wang, J., Liu, W., Kong, G., June, C. H., & Mitchell, M. J. (2026) · Nano Letters · doi:10.1021/acs.nanolett.5c06317
Markovic, U., Scalisi, E., Giunta, G., Nardo, A., Duminuco, A., Parrinello, N. L., Marino, S., Iachelli, V., Milone, G. A., Scire, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134648
“Therefore, oncological and hematological patients with active disease were included in the vulnerable group in Italy, even though a diagnosis of active malignancy represented an exclusion criterion in the pivotal trials [1,2].”
Influentialหาญผดุงกิจ, ม., & พุทธเจริญ, โ. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.1030
Wanchaijiraboon, P., Sainamthip, P., Teeyapun, N., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4189404
Vaccination for Covid-19 and Human Papillomavirus: A Comparative Study
Sharma, J. K., Gupta, U., Nagaseshu, P., Kachroo, K., & Gopalan, G. (2022) · Acta Scientific Paediatrics · doi:10.31080/aspe.2022.05.0486
Swihart, J. N., Ferreira, C. G., Shinde, A., & Shannahan, J. H. (2026) · Nanomaterials · doi:10.3390/nano16110683
Improving the fidelity of uridine analog incorporation during in vitro transcriptionPreprint
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.12.488100
COVID-19 and Historical Parallels
(2022) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-8689-1.ch007
Montecalvo, M. A., Visintainer, P., Drugge, E. D., Kowalski, K., Raffa, R., McKenna, D. F., Moronta, C., & Wormser, G. P. (2024) · Vaccines · doi:10.3390/vaccines12030327
COMPARES mRNA AND ADENOVIRUS-BASED SARS-CoV-2 VACCINES
FAADHILAH, H., WISEVA, K. O., WIDYASTUTI, F., & Wathoni, N. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021.v13s4.43822
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
Selection of Short 5′-UTR of Chemically Synthesized mRNA to Improve Translation Efficiency
Ohashi, S., Ishiguro, S., Fukunaga, T., Matsumoto, A., Hirata, M., Inagaki, M., Abe, N., Hashiya, F., & Abe, H. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c25-00048
Preparation of placenta-tropic mRNA lipid nanoparticles for pregnancy disorders
Swingle, K. L., & Mitchell, M. J. (2026) · Nature Protocols · doi:10.1038/s41596-025-01325-7
Gene Electrotransfer Clinical Trials for Cancer
Heller, R. F., & Heller, L. C. (2026) · Springer eBooks · doi:10.1007/978-3-319-26779-1_259-1
E., M., MD, G. M. G., MD, F. G. J., Hernández Silva, S. M. D., Robles Díaz, M. T. N. J., Soto Acosta, C. Y., & Landa Chávez, T. L. (2025) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2025.17.00620
Eventos adversos asociados a post-vacunas COVID 19 en pacientes de una Unidad de Medicina Familiar
Perez-Contreras, N., CONTRERAS, I. P., Santamaria-Garcia, S., et al. (2023) · Medicina e Investigación Universidad Autónoma del Estado de México · doi:10.36677/medicinainvestigacion.v11i1.20305
Biernat, A. K., Floriańczyk, A., Romanowicz, E., Kołdyj, A., Ozdarska, A., Lampart, M., Rupińska, A., Krzewska, K., & Skarakhodava, H. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3510
Hammerschmidt, S. I., Jauregui, R. G., Barros‐Martins, J., et al. (2025) · medRxiv · doi:10.1101/2025.10.09.25337642
SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines
Al-Nabolsi, M., Alhusein, D., Marchewka, T., Kucera, M., Daher, A., Venida, R., Beydoun, A. K., Surati, R., Deland, A., & Sebastian, M. (2021) · Osteopathic Family Physician · doi:10.33181/13050
Lu, R., Liang, K.-H., Chiang, H.-L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4141628
Vaccine Basics and the Development and Rollout of COVID-19 Vaccines
Mani, S., & Griffin, D. O. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00018-x
Long-Term Duration of Antibody Response to SARS CoV-2 in One of the Largest Slums of Buenos AiresPreprint
Pagotto, V. L., Luna, L., Salto, J., Manslau, M. W., Figar, S., Mistchenko, A. S., Carciofi, G., Weinberger, N., COVIDAR Group, Saldaño, A. M. G., et al. (2021) · medRxiv · doi:10.1101/2021.03.05.21253010
Vaccines for COVID-19: Effectiveness and value
McKenna, A., Rind, D. M., McQueen, R. B., et al. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1313
Chae, S. H., Park, H., Radnaabaatar, M., Park, H., & Jung, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e94
mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons
Mishra, G., Rathee, S., Garg, M., & Patil, U. K. (2025) · Current Drug Delivery · doi:10.2174/0115672018320938241121075859 · Cited by 1
Mandal, S., Ghosh, J. S., Lohani, S., Zhao, M., Cheng, Y., Luo, M., & Li, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-2790997/v1
The potential public health consequences of “mRNA vaccine stigmatization” in the US
Motta, M. (2026) · Politics and the Life Sciences · doi:10.1017/pls.2026.10027
Nehrych, T. I., Matolinets, N. V., Михайлович, Н. А., Prokopenko, N., & Kyryliuk, S. (2023) · Proceedings of the Shevchenko Scientific Society Medical Sciences · doi:10.25040/ntsh2023.01.15
Sazgary, L., Meienberg, A., Berger, C. T., & Mayr, M. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002617
Kussini, J., Mühlenbein, S., Didona, D., & Pfützner, W. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15477_g
Schlaiß, T. N., Vassilenko, M. D., Kimmel, T., Diessner, J., Wöckel, A., McNeill, R. V., Kittel‐Schneider, S., Kämmerer, U., & Bartmann, C. (2025) · Oncology Research and Treatment · doi:10.1159/000546837
“In the following year, there were also other vaccines available in Germany (Moderna COVID-19 Vaccine/ Spikevax) [9], COVID-19 Vaccine by AstraZeneca (Vaxzevria) [10] and COVID-19 Vaccine Janssen (Johnson & Johnson) [11].”
InfluentialAbdulameer, A. A., Abdullah, A. R., & Latif, I. I. (2022) · Journal of emergency medicine, trauma & acute care · doi:10.5339/jemtac.2022.ismc.13
The Role of Vaccines in Complementing Antiviral Treatments and Reducing Viral Spread
Akhtar, F., & Gul, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch001
Mweetwa, L. L., Tlhoiwe, D., Tlhoiwe, T., Tshiamo, K. O., Munsaka, S. M., Kenaope, T. J., Mothibe, G., Mokate, O., & Oluwabusola, E. T. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3027 · Cited by 1
Emerging mRNA-based nanomedicines for cancer immunotherapy
Yu, C., Wu, X., Luo, S., Wang, H., Huang, C., Zhang, L., & Zhu, D. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113288
Distinct immune signatures discriminate SARS-CoV-2 vaccine combinationsPreprint
Núñez, N. G., Schmid, J., Power, L., Alberti, C., Krishnarajah, S., Kreutmair, S., Unger, S., Blanco, S., Konigheim, B. S., Marín, C., et al. (2022) · medRxiv · doi:10.1101/2022.09.05.22279572
Sadigh, K. S., Kugeler, K. J., Bressler, S. S., Massay, S., Schmoll, E., Milroy, L., Cavanaugh, A. M., Sierocki, A., COVID-19 Vaccine Breakthrough Characterization Team, Dorough, L., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07702-x · Cited by 1
mRNA vaccines: a promising solution for incurable diseases
Ge, H., Hei, Y., & Wu, J. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3021657
Eyelid erythema after coronavirus vaccination
Bárcena-Dahl, A., Bonivento-Martínez, V., & de Pipaón, M. R.-P. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.06.021
Decoding Self vs. Non-Self: Alphavirus Cap0 Recognition and Immune Evasion
Faraj, S. E., & Filomatori, C. V. (2026) · Viruses · doi:10.3390/v18040439 · Cited by 2
“Such innova‑ tions were central to the success of mRNA vaccines against SARS‑CoV‑2 [80,81] and offer a valuable framework for the development of next‑generation vaccines targeting other RNA viruses [82].”
Bukharin, G. A., Буданова, У. А., Гезимахмаевна, Д. З., Dubrovin, E. V., & Sebyakin, Y. L. (2024) · Биологические мембраны Журнал мембранной и клеточной биологии · doi:10.31857/s0233475524040035 · Cited by 1
Lattau, S. S. J., Dudakova, A., Kummer, K., & Zschüntzsch, J. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01363-6
Brás, R., Limão, R., Caldeira, L. E., et al. (2022) · Revista Portuguesa de Imunoalergologia · doi:10.32932/rpia.2022.09.087
Arévalo, S. J. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-26102022-112347
Microcondensate‐Mediated Intracellular Infusion of mRNA Across the Plasma Membrane
Kawaguchi, Y., Kikkawa, A., Kimura, S., Abe, H., & Futaki, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202512139
Mercadé‐Besora, N., Raventós, B., Trinh, N. T., Li, H., Hayati, S., Giuliodori, A., Burkard, T., Burn, E., Català, M., Prieto‐Alhambra, D., et al. (2025) · medRxiv · doi:10.1101/2025.05.16.25327593
Diyantoro, Rantam, F. A., Juniastuti, Wijaya, A. Y., Susilowati, H., Kuncorojakti, S., & Aswin, A. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e44788
EDUKASI DAN SOSIALISASI VAKSIN COVID-19 PUSKESMAS CITEUREUP, JAWA BARAT
Tuba, S., Widyati, W., Wardhani, B. W. K., Harahap, Y., & Simorangkir, T. P. H. (2022) · JMM (Jurnal Masyarakat Mandiri) · doi:10.31764/jmm.v6i1.6004
Liu, D., Tse, C. K., Chan, R. H. M., & Zhan, C. (2021) · Research Square · doi:10.21203/rs.3.rs-590770/v1
Healy, K., Pin, E., Chen, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.30.21264377
Yu, M., Wang, L., Liu, D., Guo, J., Liu, J., Zhou, J., Mathew, A., He, Z., Wu, J., & Zhang, N. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103483 · Cited by 2
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.